Editorials
Is the Double Contour Sign Specific for Gout? Or Only for Crystal Arthritis?
J.A. Singh, N. Dalbeth ........................................ 353
Intestinal Dysbiosis and Potential Consequences of Microbiome-altering Antibiotic Use in the Pathogenesis of Human Rheumatic Disease J.U. Scher ......................... 355
Is There Hope for Juvenile Idiopathic Arthritis Patient-reported Outcomes in Support of Clinical Decisions? R.J. Burchette .................................................. 358
Ultrasound Measurement of Cartilage Thickness in Childhood Arthritis — Target the Tissue, Tailor the Technique S. Magni-Manzoni .................................................. 360

Review
The Role of Innate Immunity in OA: When Our First Line of Defense Goes On the Offensive
E.W. Orlowsky, V.B. Kraus ........................................ 363

Articles
Rates of Serious Infections and Malignancies Among Patients with RA Receiving Either TNFi or Rituximab Therapy
Facilitators and Barriers to Adherence in the Initiation Phase of DMARD Use in Patients with Arthritis Who Recently Started Their First DMARD Treatment
High Degree of Nonadherence to Disease-modifying Antirheumatic Drugs in Patients with RA
V. Rauscher, M. Engbrecht, D. van der Heijde, G. Schett, A.J. Hueber ........................................ 386
A Simplified Baseline Prediction Model for Joint Damage Progression in RA: A Step toward Personalized Medicine
Y.M.R. de Punder, P.L.C.M. van Riel, J. Fransen ........................................ 391
Characterization of Cumulative Joint Damage Patterns in Patients with RA: A Clinical, Serological, and Gene Polymorphism Perspective
Assessment of Fatigue in RA: A Psychometric Comparison of Single-item, Multiitem, and Multidimensional Measures
M.A.H. Oude Voshaar, P.M. ten Klooster, C. Bode, et al ........................................ 413
Association Between Corrected QT Interval and Inflammatory Cytokines in RA A.M. Adlan, V.F. Panoulas, J.P. Smith, J.P. Fisher, G.D. Kitas ........................................ 421
Isolated Hematuria and Sterile Pyuria May Indicate SLE Activity
J.Y.C. Ding, D. Ibañez, D.D. Gladman, M.B. Urowitz ........................................ 437
Neurocognitive Impairment in Corticosteroid-naive Patients with Active SLE: A Prospective Study K. Nishimura, M. Omori, Y. Katsumata, et al ........................................ 441
A Preliminary Study of Acoustic Radiation Force Impulse Quantification for the Assessment of Skin in dcSSc Y. Hou, Q-I. Zhu, H. Liu, et al ........................................ 449
Effects of Macitentan and Its Active Metabolite on Cultured Human SSc and Control Skin Fibroblasts M. Cutolo, P. Montagna, R. Brizzolara, et al ........................................ 456
Quantitation of Circumferential Syndesmophyte Height along the Vertebral Rim in Ankylosing Spondylitis Using Computed Tomography
S. Tan, J. Yao, J.A. Flynn, L. Yao, M.M. Ward ........................................ 472
Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with PsA A. Kavanaugh, P.J. Mease, J.J. Gomez-Reino, et al ........................................ 479
Outcome of Takayasu Arteritis with Inactive Disease at Diagnosis: The Extent of Vascular Involvement As a Predictor of Activation
S. Hong, S-H. Bae, S.M. Ahn, et al ........................................ 489